TG Therapeutics Publishes Post-Hoc Pooled Analysis Of Its Phase 3 ULTIMATE I, II Trials Of BRIUMVI To Treat Relapsing Forms Of Multiple Sclerosis

Loading news article.

TG Therapeutics Publishes Post-Hoc Pooled Analysis Of Its Phase 3 ULTIMATE I, II Trials Of BRIUMVI To Treat Relapsing Forms Of Multiple Sclerosis | WAPE

TG Therapeutics Publishes Post-Hoc Pooled Analysis Of Its Phase 3 ULTIMATE I, II Trials Of BRIUMVI To Treat Relapsing Forms Of Multiple Sclerosis

Article summary

Related companies

Comments —